# The CAPTAIN Trial: Cerebrolysin Asian Pacific Trial in Acute Brain Injury and Neurorecovery

> **NCT01606111** · PHASE4 · TERMINATED · sponsor: **Ever Neuro Pharma GmbH** · enrollment: 46 (actual)

## Conditions studied

- Traumatic Brain Injury

## Interventions

- **DRUG:** Cerebrolysin
- **DRUG:** 0.9% NaCl, saline

## Key facts

- **NCT ID:** NCT01606111
- **Lead sponsor:** Ever Neuro Pharma GmbH
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2013-09
- **Primary completion:** 2015-07
- **Final completion:** 2015-07
- **Target enrollment:** 46 (ACTUAL)
- **Why stopped:** Poor patient recruitment
- **Last updated:** 2020-02-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01606111

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01606111, "The CAPTAIN Trial: Cerebrolysin Asian Pacific Trial in Acute Brain Injury and Neurorecovery". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01606111. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*